MedPath

A Clinical study to which Anti-emetic effect of 5-HT3RA is evaluated by using MAT in HEC for gastric cancer.

Not Applicable
Conditions
Gastric Cancer
Registration Number
JPRN-UMIN000004135
Lead Sponsor
Kochi Health Sciences Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) Hypersensitivity or severe drug allergy for Aloxi or other 5-HT3RA. 2) Hypersensitivity or severe drug allergy for dexamethasone. 3) Any other patient whom the physician in charge of the study judges to be not eligible

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The level of each observation point of the nausea and vomiting before and after 5- HT3RA change is evaluated by MAT.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath